• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»CatalYm

Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.

By Pallavi Madhiraju on April 23, 2026   Pharma & Biotech  

Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.

CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.

Recent Posts

  • BNB Plus completes record LineaDNA order as strategic review puts LineaRx in sharper focus
  • Can Bausch + Lomb’s PreserVision AREDS3 shift the AMD supplement market beyond AREDS2 alone?
  • Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
  • GE HealthCare’s LUMINA trial could test whether manganese MRI contrast is finally ready for the mainstream
  • Can Karius and Mayo Clinic Laboratories push metagenomic infectious disease testing closer to routine hospital use?
  • What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis
  • Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies
  • Can Neurona Therapeutics validate regenerative cell therapy in epilepsy with Phase 3 EPIC trial
  • What Tempest Therapeutics, Inc.’s CAR-T strategy reveals about the next phase of cell therapy competition
  • Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?
  • Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
  • Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes